NEW YORK, Sept. 02, 2022 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is notifying investors that a class action lawsuit has been filed against 1Globe Capital LLC (“1Globe”) and certain of its officers, on behalf of all natural and legal persons who own Sinovac Biotech Ltd. (“Sinovac” or the “Company”) purchased or otherwise acquired SVA Shares between April 11, 2016 and February 22, 2019 (the “Collection Period”). Such investors are encouraged to join this case by visiting the company’s website: www.bgandg.com/sva.
This class action seeks damages against the defendants for alleged violations of federal securities laws.
The lawsuit alleges that the defendants made false and/or misleading statements and/or failed to disclose the following: (1) 1Globe Capital LLC and Jiaqiang Li (“Li”) share beneficial ownership of 20% or more of the common stock of Sinovac; (2) 1Globe’s actions in connection with the annual meeting, including 1Globe’s and Li’s participation in efforts to replace four of Sinovac’s five acting directors; (3) Defendants’ agreements and relationships with each other regarding their Sinovac shares; and (4) its plans to acquire additional Sinovac stock.
A class action lawsuit has already been filed. If you would like to see a copy of the complaint, you can visit the firm’s website: www.bgandg.com/sva or you can contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Sinovac, you have until October 17, 2022 to apply for the court to appoint you lead plaintiff. Your ability to participate in a recovery does not require you to serve as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC represents investors in class action lawsuits alleging securities fraud and shareholder derivative lawsuits. The company has recovered hundreds of millions of dollars for investors nationwide. attorney advertising. Previous results do not guarantee similar …
